Format

Send to:

Choose Destination

Ovarian carcinoma

MedGen UID:
1648335
Concept ID:
C4721610
Neoplastic Process
Synonyms: Cancer, Epithelial Ovarian; Cancer, Ovarian Epithelial; Cancers, Epithelial Ovarian; Cancers, Ovarian Epithelial; Carcinoma, Epithelial Ovarian; Carcinoma, Ovarian Epithelial; Carcinomas, Epithelial Ovarian; Carcinomas, Ovarian Epithelial; Epithelial Cancer, Ovarian; Epithelial Cancers, Ovarian; Epithelial Carcinoma, Ovarian; Epithelial Carcinomas, Ovarian; Epithelial Ovarian Cancer; Epithelial Ovarian Cancers; Epithelial Ovarian Carcinoma; Epithelial Ovarian Carcinomas; Ovarian Cancer, Epithelial; Ovarian Cancers, Epithelial; Ovarian Carcinoma, Epithelial; Ovarian Carcinomas, Epithelial; Ovarian Epithelial Cancer; Ovarian Epithelial Cancers; Ovarian Epithelial Carcinoma; Ovarian Epithelial Carcinomas
 
HPO: HP:0025318

Definition

A malignant neoplasm originating from the surface ovarian epithelium. [from HPO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • Ovarian carcinoma

Conditions with this feature

Gorlin syndrome
MedGen UID:
2554
Concept ID:
C0004779
Neoplastic Process
Nevoid basal cell carcinoma syndrome (NBCCS) is characterized by the development of multiple jaw keratocysts, frequently beginning in the second decade of life, and/or basal cell carcinomas (BCCs) usually from the third decade onward. Approximately 60% of individuals have a recognizable appearance with macrocephaly, frontal bossing, coarse facial features, and facial milia. Most individuals have skeletal anomalies (e.g., bifid ribs, wedge-shaped vertebrae). Ectopic calcification, particularly in the falx, is present in more than 90% of affected individuals by age 20 years. Cardiac and ovarian fibromas occur in approximately 2% and 20% of individuals respectively. Approximately 5% of all children with NBCCS develop medulloblastoma (primitive neuroectodermal tumor), generally the desmoplastic subtype. The risk of developing medulloblastoma is substantially higher in individuals with an SUFU pathogenic variant (33%) than in those with a PTCH1 pathogenic variant (<2%). Peak incidence is at age one to two years. Life expectancy in NBCCS is not significantly different from average.
Cowden syndrome
MedGen UID:
5420
Concept ID:
C0018553
Neoplastic Process
Cowden syndrome-1 is a hamartomatous disorder characterized by macrocephaly, facial trichilemmomas, acral keratoses, papillomatous papules, and an increased risk for the development of breast, thyroid, and endometrial carcinoma. Bannayan-Riley-Ruvalcaba syndrome (BRRS), previously thought be distinct, shared clinical characteristics with Cowden syndrome, such as hamartomatous polyps of the gastrointestinal tract, mucocutaneous lesions, and increased risk of developing neoplasms, but had the additional features of developmental delay, macrocephaly, lipomas, hemangiomas, and pigmented speckled macules of the glans penis in males. Because features of BRRS and Cowden syndrome have been found in individuals within the same family with the same PTEN mutation, Cowden syndrome-1 and BRRS are considered to be the same disorder with variable expression and age-related penetrance (summary by Marsh et al., 1999, Lachlan et al., 2007, and Blumenthal and Dennis, 2008). Approximately 80% of patients reported with Cowden syndrome and 60% with BRSS have PTEN mutations (Blumenthal and Dennis, 2008). Some patients with Cowden syndrome may have immune system defects resulting in increased susceptibility to infections (summary by Browning et al., 2015).
Lhermitte-Duclos disease
MedGen UID:
140251
Concept ID:
C0391826
Neoplastic Process
A very rare disorder characterized by abnormal development and enlargement of the cerebellum, and an increased intracranial pressure.
Cerebelloparenchymal Disorder VI
MedGen UID:
331813
Concept ID:
C1834711
Disease or Syndrome
Cerebellar Granule Cell Hypertrophy and Megalencephaly
MedGen UID:
371886
Concept ID:
C1834712
Disease or Syndrome
PTEN hamartoma tumor syndrome with granular cell tumor
MedGen UID:
400984
Concept ID:
C1866376
Neoplastic Process
Proteus-like syndrome
MedGen UID:
356222
Concept ID:
C1866398
Disease or Syndrome
Proteus like syndrome describes patients who do not meet the diagnostic criteria for Proteus syndrome but who share a multitude of characteristic clinical features of the disease. The prevalence is unknown. The main clinical features include skeletal overgrowth, hamartomatous overgrowth of multiple tissues, cerebriform connective tissue nevi, vascular malformations and linear epidermal nevi. Mutations in the PTEN gene are found in 50% of Proteus-like syndrome cases, making them a part of the PTEN hamartoma syndrome group.
PTEN hamartoma tumor syndrome
MedGen UID:
368366
Concept ID:
C1959582
Neoplastic Process
The PTEN hamartoma tumor syndrome (PHTS) includes Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), and PTEN-related Proteus-like syndrome. CS is a multiple hamartoma syndrome with a high risk for benign and malignant tumors of the thyroid, breast, kidney, and endometrium. Affected individuals usually have macrocephaly, trichilemmomas, and papillomatous papules, and present by the late 20s. The lifetime risk of developing breast cancer is 85%, with an average age of diagnosis between 38 and 46 years. The lifetime risk for thyroid cancer (usually follicular, rarely papillary, but never medullary thyroid cancer) is approximately 35%. The lifetime risk for renal cell cancer (predominantly of papillary histology) is 34%. The risk for endometrial cancer may approach 28%. BRRS is a congenital disorder characterized by macrocephaly, intestinal hamartomatous polyposis, lipomas, and pigmented macules of the glans penis. PS is a complex, highly variable disorder involving congenital malformations and hamartomatous overgrowth of multiple tissues, as well as connective tissue nevi, epidermal nevi, and hyperostoses. Proteus-like syndrome is undefined but refers to individuals with significant clinical features of PS who do not meet the diagnostic criteria for PS.
Breast-ovarian cancer, familial 3
MedGen UID:
462009
Concept ID:
C3150659
Finding

Recent clinical studies

Etiology

Li Y, Huo FF, Wen YY, Jiang M
Biomed Res Int 2021;2021:6680036. Epub 2021 Apr 30 doi: 10.1155/2021/6680036. PMID: 33997040Free PMC Article
Leenen S, Hermens M, de Vos van Steenwijk PJ, Bekkers RLM, van Esch EMG
Cancer Immunol Immunother 2021 Jul;70(7):1821-1829. Epub 2021 Jan 7 doi: 10.1007/s00262-020-02831-1. PMID: 33411080
Abou-El-Naga AM, Abo El-Khair SM, Mahmoud AZ, Hamza M, Elshazli RM
J Biochem Mol Toxicol 2021 Feb;35(2):e22637. Epub 2020 Sep 30 doi: 10.1002/jbt.22637. PMID: 32997381
Chen J, Chen K, Zhou Z, Huang L, Cai Y, Tu H, Zhang X
Curr Probl Cancer 2020 Oct;44(5):100555. Epub 2020 Jan 28 doi: 10.1016/j.currproblcancer.2020.100555. PMID: 32057463
Babay W, Ben Yahia H, Boujelbene N, Zidi N, Laaribi AB, Kacem D, Ben Ghorbel R, Boudabous A, Ouzari HI, Rizzo R, Rebmann V, Mrad K, Zidi I
Hum Immunol 2018 Jun;79(6):463-470. Epub 2018 Mar 2 doi: 10.1016/j.humimm.2018.02.012. PMID: 29499226

Diagnosis

An H, Wang Y, Wong EMF, Lyu S, Han L, Perucho JAU, Cao P, Lee EYP
Eur Radiol 2021 Jul;31(7):5050-5058. Epub 2021 Jan 6 doi: 10.1007/s00330-020-07565-3. PMID: 33409777
Abou-El-Naga AM, Abo El-Khair SM, Mahmoud AZ, Hamza M, Elshazli RM
J Biochem Mol Toxicol 2021 Feb;35(2):e22637. Epub 2020 Sep 30 doi: 10.1002/jbt.22637. PMID: 32997381
Hollis RL, Carmichael J, Meynert AM, Churchman M, Hallas-Potts A, Rye T, MacKean M, Nussey F, Semple CA, Herrington CS, Gourley C
Am J Obstet Gynecol 2019 Sep;221(3):245.e1-245.e15. Epub 2019 May 2 doi: 10.1016/j.ajog.2019.04.035. PMID: 31055034Free PMC Article
Li Y, Tan C, Liu L, Han L
J Obstet Gynaecol Res 2018 Apr;44(4):764-771. Epub 2018 Feb 12 doi: 10.1111/jog.13576. PMID: 29431239Free PMC Article
Hong B, Zhang J, Yang W
Mol Med Rep 2018 Feb;17(2):2837-2844. Epub 2017 Dec 8 doi: 10.3892/mmr.2017.8229. PMID: 29257268Free PMC Article

Therapy

An H, Wang Y, Wong EMF, Lyu S, Han L, Perucho JAU, Cao P, Lee EYP
Eur Radiol 2021 Jul;31(7):5050-5058. Epub 2021 Jan 6 doi: 10.1007/s00330-020-07565-3. PMID: 33409777
Johnson KE, Popratiloff A, Fan Y, McDonald S, Godleski JJ
Gynecol Oncol 2020 Nov;159(2):527-533. Epub 2020 Sep 22 doi: 10.1016/j.ygyno.2020.09.028. PMID: 32977988
Guo L, Zhang Y, Yang Z, Peng H, Wei R, Wang C, Feng M
ACS Nano 2019 Feb 26;13(2):1078-1096. Epub 2019 Jan 4 doi: 10.1021/acsnano.8b08872. PMID: 30608136
Corno C, Gatti L, Arrighetti N, Carenini N, Zaffaroni N, Lanzi C, Perego P
Biochem Pharmacol 2017 Jul 15;136:40-50. Epub 2017 Apr 9 doi: 10.1016/j.bcp.2017.04.002. PMID: 28404378
Zhan L, Zhang Y, Wang W, Song E, Fan Y, Li J, Wei B
Oncotarget 2016 Dec 13;7(50):83476-83487. doi: 10.18632/oncotarget.13080. PMID: 27825125Free PMC Article

Prognosis

Li Y, Huo FF, Wen YY, Jiang M
Biomed Res Int 2021;2021:6680036. Epub 2021 Apr 30 doi: 10.1155/2021/6680036. PMID: 33997040Free PMC Article
An H, Wang Y, Wong EMF, Lyu S, Han L, Perucho JAU, Cao P, Lee EYP
Eur Radiol 2021 Jul;31(7):5050-5058. Epub 2021 Jan 6 doi: 10.1007/s00330-020-07565-3. PMID: 33409777
Chen J, Chen K, Zhou Z, Huang L, Cai Y, Tu H, Zhang X
Curr Probl Cancer 2020 Oct;44(5):100555. Epub 2020 Jan 28 doi: 10.1016/j.currproblcancer.2020.100555. PMID: 32057463
Hollis RL, Carmichael J, Meynert AM, Churchman M, Hallas-Potts A, Rye T, MacKean M, Nussey F, Semple CA, Herrington CS, Gourley C
Am J Obstet Gynecol 2019 Sep;221(3):245.e1-245.e15. Epub 2019 May 2 doi: 10.1016/j.ajog.2019.04.035. PMID: 31055034Free PMC Article
Babay W, Ben Yahia H, Boujelbene N, Zidi N, Laaribi AB, Kacem D, Ben Ghorbel R, Boudabous A, Ouzari HI, Rizzo R, Rebmann V, Mrad K, Zidi I
Hum Immunol 2018 Jun;79(6):463-470. Epub 2018 Mar 2 doi: 10.1016/j.humimm.2018.02.012. PMID: 29499226

Clinical prediction guides

Li Y, Huo FF, Wen YY, Jiang M
Biomed Res Int 2021;2021:6680036. Epub 2021 Apr 30 doi: 10.1155/2021/6680036. PMID: 33997040Free PMC Article
An H, Wang Y, Wong EMF, Lyu S, Han L, Perucho JAU, Cao P, Lee EYP
Eur Radiol 2021 Jul;31(7):5050-5058. Epub 2021 Jan 6 doi: 10.1007/s00330-020-07565-3. PMID: 33409777
Voutsadakis IA
Eur J Obstet Gynecol Reprod Biol 2021 Jan;256:172-178. Epub 2020 Nov 12 doi: 10.1016/j.ejogrb.2020.11.021. PMID: 33246201
Chen J, Chen K, Zhou Z, Huang L, Cai Y, Tu H, Zhang X
Curr Probl Cancer 2020 Oct;44(5):100555. Epub 2020 Jan 28 doi: 10.1016/j.currproblcancer.2020.100555. PMID: 32057463
Babay W, Ben Yahia H, Boujelbene N, Zidi N, Laaribi AB, Kacem D, Ben Ghorbel R, Boudabous A, Ouzari HI, Rizzo R, Rebmann V, Mrad K, Zidi I
Hum Immunol 2018 Jun;79(6):463-470. Epub 2018 Mar 2 doi: 10.1016/j.humimm.2018.02.012. PMID: 29499226

Recent systematic reviews

Ge S, Xing Q, Zhang A, Wang Y
Medicine (Baltimore) 2021 Jan 15;100(2):e23904. doi: 10.1097/MD.0000000000023904. PMID: 33466133Free PMC Article
Voutsadakis IA
Eur J Obstet Gynecol Reprod Biol 2021 Jan;256:172-178. Epub 2020 Nov 12 doi: 10.1016/j.ejogrb.2020.11.021. PMID: 33246201
Goulding EA, Simcock B, McLachlan J, van der Griend R, Sykes P
Aust N Z J Obstet Gynaecol 2020 Feb;60(1):27-33. Epub 2019 Dec 17 doi: 10.1111/ajo.13105. PMID: 31849044
Xiao Y, Xie S, Zhang N, Wang J, Lv C, Guo J, Yang Q
Gynecol Obstet Invest 2018;83(3):209-219. Epub 2017 Dec 21 doi: 10.1159/000485618. PMID: 29402804
Hoogendam JP, Vlek CA, Witteveen PO, Verheijen R, Zweemer RP
BJOG 2017 Feb;124(3):370-378. Epub 2016 Jul 22 doi: 10.1111/1471-0528.14226. PMID: 27444115

Supplemental Content

Table of contents

    Clinical resources

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...
    Support Center